

ASX ANNOUNCEMENT

16 February 2022

Cann to present half year results webinar

16 February 2022 – Cann Group Limited (ASX: CAN) (**Cann**) is pleased to invite shareholders, investors and interested parties to an investor update webinar and Q&A with CEO Peter Crock, COO Shane Duncan and CFO Deborah Ambrosini.

The webinar will be held on **Friday 18 February 2022 at 9:30am** (Melbourne time).

For the Q&A session, investors are invited to send questions prior to the webinar to matt@nwrcommunications.com.au

Register for the webinar at the following link:

https://us02web.zoom.us/webinar/register/WN_gdICP_95RnGuNffegE0rYg

After registering, you will receive a confirmation email containing information about joining the webinar as well as dial-in details for those that would prefer to join by phone. A recording will be available at the above link shortly after the conclusion of the live session.

Authorised for release by Geraldine Farrell, Company Secretary, Cann Group Limited.

For all media enquiries please contact:

Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

For all other information please contact:

Peter Crock
CEO
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

Clive Fanning
Head of Investor Relations
Cann Group Limited
+61 3 9095 7088
clive.fanning@canngrouponlimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. Cann also owns Satipharm, a Europe-based business exclusively licensed to manufacture, develop and market a proprietary delivery system for cannabinoids. Cann has established research, cultivation and GMP manufacturing facilities in Melbourne and is developing a state-of-the-art cultivation and manufacturing facility near Mildura, Victoria. Cann Group has established a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products.

Learn more at: www.canngrouponlimited.com | www.satipharm.com